A composite probiotic for resisting Helicobacter pylori infection and its application
By combining the Lactobacillus paracasei LC24 strain and Lactobacillus rhamnosus LRa05 strain, the problem of poor anti-Herrelic pylori infection in the prior art was solved, and the growth of Helicobacillus pylori was inhibited and the growth of Helicobacillus and The inflammatory response enhances the body's antioxidant and stomach digestive abilities.
Patent Information
- Application Number
- CN202410903836.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-08
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-07-08
AI Technical Summary
The prior art is still in the initial stage in the prevention and treatment of Helicobacter pylori infection. The lack of effective probiotic agents makes it difficult to effectively inhibit the growth and colonization of Helicobacter pylori, resulting in the occurrence of gastritis and peptic ulcers.
The combination of Lactobacillus paracasei LC24 strain and Lactobacillus rhamnosus LRa05 strain was adopted to inhibit the colonization and growth of Helicobacillus pylori, regulate the inflammatory response, enhance the body's antioxidant ability, and significantly reduce the infection of Helicobacillus pylori IgG antibodies and endotoxin levels improve pepsin activity.
It significantly improves the effect of anti-Herrelic pylori infection, enhances the body's antioxidant ability and gastric digestion ability, reduces the inflammatory response, and the combination of the two strains is safe and difficult to develop resistance.
Smart Images

Figure CN118440875B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms and relates to a composite probiotic for resisting Helicobacter pylori infection and application thereof. Background Art
[0002] Helicobacter pylori ( Helicobacter pylori, HP ) is a type of aerobic bacteria that is spiral or arc-shaped under a microscope and is closely related to the occurrence of chronic gastritis, peptic ulcers and gastric cancer. It has high nutritional requirements during its growth and reproduction, and can resist gastric acid. After entering the human body, it can survive and reproduce in the gastric mucosal epithelial cells. In the process, it will produce a large number of invasive factors and toxins, which promote the occurrence of peptic ulcers and even gastric cancer. The pathogenic mechanism of Helicobacter pylori for gastritis is mainly that after colonization in the stomach, it can produce a large number of virulence factors. These virulence factors can cause the gastric mucosal epithelial cells to degenerate, thereby destroying the normal gastric mucosal barrier, causing gastric acid to erode the gastric mucosa, and then causing gastritis; and the pathogenic mechanism of Helicobacter pylori for peptic ulcer is that while Helicobacter pylori destroys the gastric mucosal barrier, it may also stimulate the secretion of gastric acid, aggravate the damage of the gastric mucosa and duodenal mucosa, and then cause gastric ulcers or duodenal ulcers.
[0003] Probiotics have shown great potential in preventing and treating Helicobacter pylori infection. As living microorganisms, probiotics can bring health benefits to the host in a variety of ways when ingested in sufficient amounts. The mechanism of action of probiotics against Helicobacter pylori mainly includes direct antibacterial effect, competitive inhibition of Helicobacter pylori colonization, and improvement of host anti-inflammatory and barrier function. By producing antibacterial substances, competing with Helicobacter pylori for nutrients and adhesion sites, and regulating the host immune response, probiotics can effectively inhibit the growth and colonization of Helicobacter pylori, thereby reducing or preventing Helicobacter pylori infection.
[0004] The application of probiotics in the prevention and treatment of gastric diseases caused by Helicobacter pylori is still in its early stages, and there are still few strategies. Therefore, the development of more probiotics against Helicobacter pylori can provide new ideas and methods for the treatment of gastric diseases caused by Helicobacter pylori. Summary of the invention
[0005] In view of the deficiencies in the prior art, the object of the present invention is to provide a composite probiotic for resisting Helicobacter pylori infection and application thereof.
[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0007] In a first aspect, the present invention provides a composite probiotic for resisting Helicobacter pylori infection, wherein the composite probiotic for resisting Helicobacter pylori infection is composed of Lactobacillus paracasei with a preservation number of CGMCC No.24411. Lactobacillus paracasei LC24 strain and Lactobacillus rhamnosus with a deposit number of CGMCC No. 24377 Lactobacillus rhamnosus LRa05 strain composition.
[0008] The present invention creatively develops a new probiotic compounding method and a new anti-Helicobacter pylori infection strategy, namely, Lactobacillus paracasei Lactobacillus paracasei LC24 strain and Lactobacillus rhamnosus Lactobacillus rhamnosus The LRa05 strain was used in combination, and it was found that the two strains could cooperate with each other, promote each other, and synergize in the effect of anti-Helicobacter pylori infection, which was specifically manifested in: (1) inhibiting the colonization and growth of Helicobacter pylori; (2) having good co-aggregation characteristics with Helicobacter pylori; (3) significantly reducing the level of IgG antibodies and endotoxin levels in mice infected with Helicobacter pylori; (4) regulating the levels of serum inflammatory factors such as IL-17A, IL-23, IFN-β, and IFN-γ in mice infected with Helicobacter pylori, and regulating the mouse inflammatory response regulatory transcription factor FoxP3, inhibiting the inflammatory response caused by Helicobacter pylori infection; (5) significantly increasing the levels of catalase CAT and superoxide dismutase SOD, enhancing the body's antioxidant capacity; (6) increasing the activity of pepsin in the gastric tissue of Helicobacter pylori-infected mice to enhance gastric digestion. When the amount of bacteria used was the same, the combination of the two strains significantly improved the effect of anti-Helicobacter pylori infection compared with the intervention method without either strain. At the same time, both bacteria are probiotics, the products are highly safe and not prone to resistance.
[0009] Preferably, the ratio of the number of viable cells of the LC24 strain to the LRa05 strain is 1:10-10:1, for example, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, etc. Other specific point values within the above numerical range can be selected, and they will not be described one by one here.
[0010] In a second aspect, the present invention provides a probiotic for resisting Helicobacter pylori infection, wherein the strain in the probiotic is the composite probiotic described in the first aspect.
[0011] Preferably, the live bacteria content of the composite probiotics in the probiotic agent is not less than 1×10 9 CFU / g or 1×10 9 CFU / mL, for example 1×10 9 CFU / g (CFU / mL), 1×10 10 CFU / g (CFU / mL), 5×10 10CFU / g (CFU / mL), 1×10 11 CFU / g (CFU / mL), 3×10 11 CFU / g (CFU / mL), 5×10 11 CFU / g (CFU / mL), 1×10 12 CFU / g (CFU / mL), 1×10 13 CFU / g (CFU / mL), etc. Other specific point values within this numerical range can be selected and will not be described here one by one.
[0012] Preferably, the dosage form of the probiotics includes solutions, lyophilized powders, capsules, tablets or granules. The dosage form of the probiotics involved in the present invention is not limited, including the most commonly used solutions, lyophilized powders, or further prepared capsules, tablets or granules.
[0013] Preferably, the probiotic is in the form of a solution, which is prepared by the following method:
[0014] The LC24 strain and the LRa05 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively and resuspended with a solvent to obtain a LC24 bacterial suspension and a LRa05 bacterial suspension; the LC24 bacterial suspension and the LRa05 bacterial suspension are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent.
[0015] Preferably, the probiotic is in the form of a freeze-dried powder, which is prepared by the following method:
[0016] The LC24 strain and the LRa05 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively, mixed with a protective agent and freeze-dried to obtain LC24 bacterial powder and LRa05 bacterial powder; the LC24 bacterial powder and the LRa05 bacterial powder are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent.
[0017] In a third aspect, the present invention provides use of the composite probiotic described in the first aspect or the probiotic agent described in the second aspect in the preparation of a medicament for preventing, improving or treating gastric disease caused by Helicobacter pylori infection.
[0018] Preferably, the medicine further contains excipients.
[0019] Preferably, the auxiliary materials include any one or a combination of at least two of fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, colorants, pH regulators, antioxidants, antibacterial agents or buffers.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] The present invention creatively develops a new probiotic compounding method and a new anti-Helicobacter pylori infection strategy, namely, Lactobacillus paracasei Lactobacillus paracasei LC24 strain and Lactobacillus rhamnosus Lactobacillus rhamnosus The LRa05 strain was used in combination, and it was found that the two strains could cooperate with each other, promote each other, and synergize in the effect of anti-Helicobacter pylori infection, which was specifically manifested in: (1) inhibiting the colonization and growth of Helicobacter pylori; (2) having good co-aggregation characteristics with Helicobacter pylori; (3) significantly reducing the level of IgG antibodies and endotoxin levels in mice infected with Helicobacter pylori; (4) regulating the levels of serum inflammatory factors such as IL-17A, IL-23, IFN-β, and IFN-γ in mice infected with Helicobacter pylori, and regulating the mouse inflammatory response regulatory transcription factor FoxP3, inhibiting the inflammatory response caused by Helicobacter pylori infection; (5) significantly increasing the levels of catalase CAT and superoxide dismutase SOD, enhancing the body's antioxidant capacity; (6) increasing the activity of pepsin in the gastric tissue of Helicobacter pylori-infected mice to enhance gastric digestion. When the amount of bacteria used was the same, the combination of the two strains significantly improved the effect of anti-Helicobacter pylori infection compared with the intervention method without either strain. At the same time, both bacteria are probiotics, the products are highly safe and not prone to resistance.
[0022] The LC24 strain involved in the present invention is classified as Lactobacillus paracasei Lactobacillus paracasei The depository is the General Microbiology Center of China Microbiological Culture Collection Administration. The deposit date is February 21, 2022. The deposit number is CGMCC No.24411. The address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0023] The LRa05 strain involved in the present invention is classified and named as Lactobacillus rhamnosus Lactobacillus rhamnosus The depository is the General Microbiology Center of China Microbiological Culture Collection Administration. The deposit date is January 24, 2022. The deposit number is CGMCC No.24377. The address is: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 This is the laser confocal micrograph of the coaggregation ability test of LC24 strain and LRa05 strain with Helicobacter pylori;
[0025] Figure 2 This is a picture showing the results of Helicobacter pylori colonization in gastric mucosal tissue;
[0026] Figure 3This is a statistical result graph of the anti-Hp-IgG antibody level in the serum of each group of mice;
[0027] Figure 4 This is the statistical result diagram of serum endotoxin levels of mice in each group;
[0028] Figure 5 This is a statistical result graph of serum IL-17A levels in each group of mice;
[0029] Figure 6 This is a statistical graph of the serum IL-23 levels of mice in each group;
[0030] Figure 7 This is a statistical graph of serum IFN-β levels in each group of mice;
[0031] Figure 8 This is a statistical graph of serum IFN-γ levels in each group of mice;
[0032] Fig. 9 is the statistical result diagram of Foxp3 protein expression level in serum of each group of mice;
[0033] Fig.10 is the statistical result graph of serum catalase (CAT) level of each group of mice;
[0034] Fig.11 This is the statistical result of serum superoxide dismutase (SOD) level in each group of mice;
[0035] Fig.12 This is a statistical graph of the expression level of pepsin in the gastric tissue of each group of mice. DETAILED DESCRIPTION
[0036] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0037] The culture medium formula involved in the following examples is as follows:
[0038] MRS medium: peptone 10g / L, beef extract 10g / L, glucose 20g / L, sodium acetate 2g / L, yeast powder 5g / L, diammonium hydrogen citrate 2g / L, K2PO4·3H2O 2.6g / L, MgSO4·7H2O 0.1g / L, MnSO4 0.05g / L, Tween 801mL / L, cysteine hydrochloride 0.5g / L.
[0039] The LC24 strain involved in the following examples is classified and named as Lactobacillus paracasei Lactobacillus paracaseiThe deposit date is February 21, 2022, and the deposit number is CGMCC No.24411.
[0040] The LRa05 strain involved in the following examples is classified and named as Lactobacillus rhamnosus Lactobacillus rhamnosus The deposit date is January 24, 2022, and the deposit number is CGMCC No.24377.
[0041] The following method for preparing a bacterial suspension involves: taking out the desired strain from a -80°C refrigerator, inoculating it into an MRS liquid culture medium at an inoculum size of 2% (v / v), culturing it at 37°C for 24 hours for activation, and continuously activating it twice to obtain an activated solution; inoculating the activated solution into an MRS liquid culture medium at an inoculum size of 2% (v / v), culturing it at 37°C for 24 hours to obtain a bacterial solution; centrifuging the bacterial solution at 5000 rpm at 4°C for 10 min, filtering it to obtain bacterial bodies, and resuspending the bacterial bodies in a PBS solution to obtain the product.
[0042] The experimental results were statistically analyzed using ggplot2 in R language. Compared with the control group, ### represents p<0.001, ## represents p<0.01, and # represents p<0.05; compared with the model group, *** represents p<0.001, ** represents p<0.01, and * represents p<0.05.
[0043] The Lactobacillus reuteri DSM17648 involved in the following examples was commercially available; the Helicobacter pylori SS1 (H. pylori SS1) was purchased from Guangdong Provincial Microbiological Culture Collection Center.
[0044] Example 1
[0045] Inhibition zone detection of strains against Helicobacter pylori SS1 strain:
[0046] Helicobacter pylori SS1 was inoculated on Columbia blood agar plates and cultured in a 37°C three-gas incubator (5% O2, 10% CO2, 85% N2) for 48 h to obtain Helicobacter pylori blood agar plates; Helicobacter pylori SS1 cells were collected, washed twice with PBS buffer, and then resuspended in BHI liquid medium to adjust the cell concentration to 10 6 CFU / mL, obtain Helicobacter pylori SS1 bacterial suspension; pour it into a sterile plate with an Oxford cup, wait for the culture medium to solidify and take out the Oxford cup. Then, 10 9 CFU / mL LC24 bacterial suspension, LRa05 bacterial suspension and Lactobacillus reuteri DSM17648 bacterial suspension (positive control group) were inoculated into the blood plate wells, and the MRS liquid culture medium was inoculated as the blank control group. After 72 hours of culture, the diameter of the inhibition zone was observed and measured. The results are shown in Table 1.
[0047] Table 1
[0048]
[0049] From the data results in Table 1, it can be seen that compared with the control strain DSM17648, strains LC24 and LRa05 showed stronger inhibition ability, and the diameter of the inhibition zone against Helicobacter pylori SS1 reached 15.8 mm and 15.2 mm.
[0050] Example 2
[0051] Detection of the urease activity inhibition of Helicobacter pylori SS1 strain:
[0052] The concentration of Helicobacter pylori SS1 was adjusted to 10 7 CFU / mL. Take 10 μL of LC24 bacterial suspension, LRa05 bacterial suspension and Lactobacillus reuteri DSM17648 bacterial suspension (10 9 CFU / mL) and 40 μL of the above-mentioned Helicobacter pylori SS1 bacterial suspension were added to a 96-well plate and placed in a three-gas incubator for 48 h. Then 150 μL of urease indicator was taken out and the absorbance was measured with a 550 nm microplate reader after shaking to calculate the urease activity inhibition rate (%); the control group was measured with BHI liquid culture medium instead of bacterial suspension. Urease indicator formula: 0.9% NaCl, 20 mmol / L urea, 14 μg / mL phenol red, and the pH was adjusted to 6.8 with HCl. The results are shown in Table 2.
[0053] Table 2
[0054]
[0055] From the data results in Table 2, it can be seen that compared with the control strain DSM17648, strains LC24 and LRa05 showed stronger ability to inhibit the urease activity of Helicobacter pylori strain SS1.
[0056] Example 3
[0057] Hydrophobicity test of strains:
[0058] PBS was used to adjust the OD of LC24 and LRa05 bacterial suspensions. 600 0.50, take 2 mL of bacterial suspension and mix with 2 mL of hydrophobic solvent xylene, and let stand for 30 min. Take the lower aqueous phase and measure the absorbance at a wavelength of 600 nm. Calculate the hydrophobicity according to the following formula:
[0059] Strain hydrophobicity = (A x -A y ) / A x ×100%
[0060] A x : Absorbance of the aqueous phase at a wavelength of 600 nm before mixing with xylene;
[0061] A y : The absorbance of the aqueous phase at a wavelength of 600 nm after mixing with xylene and letting it stand for 30 min.
[0062] The results are shown in Table 3.
[0063] Table 3
[0064]
[0065] From the data results in Table 3, it can be seen that strains LC24 and LRa05 exhibit excellent hydrophobicity, which helps to improve their intestinal survival rate and enhance their adhesion to the intestinal mucosa, thereby more effectively exerting their probiotic effects.
[0066] Example 4
[0067] Self-aggregation ability test of strains:
[0068] PBS was used to adjust the OD of LC24 and LRa05 bacterial suspensions. 600 The absorbance of the upper layer solution at a wavelength of 600 nm was measured at 2h, 4h, 8h, and 24h, and recorded. The autoaggregation rate was calculated according to the following formula:
[0069] Self-aggregation rate = (A x -A y ) / A x ×100%
[0070] A x : absorbance value at 0 h; A y : The absorbance value of th.
[0071] The results are shown in Table 4.
[0072] Table 4
[0073]
[0074] From the data results in Table 4, it can be seen that with the extension of time, the self-aggregation ability of LC24 and LRa05 gradually increases, reaching 28.65% for LC24 and 22.32% for LRa05 at 24 h.
[0075] Example 5
[0076] Detection of co-aggregation ability of strains with Helicobacter pylori:
[0077] PBS was used to adjust the OD values of LC24 bacterial suspension, LRa05 bacterial suspension and Helicobacter pylori SS1 bacterial suspension. 600 The ratio of LC24 and LRa05 bacterial suspensions to H. pylori SS1 was 0.50, and the same volume of LC24 and LRa05 bacterial suspensions were mixed with H. pylori SS1 bacterial suspensions, mixed with a vortex shaker for 20 s, and incubated at 37°C. The absorbance values of the upper layer solution at a wavelength of 600 nm were measured at 0.25h, 0.5h, 1h, 1.5h, 2h, 4h, 8h, and 24h, and recorded. The coagulation rate was calculated according to the following formula:
[0078] Coaggregation rate (%) = [(A x +A y )-2A t(x+y )] / (A x +A y )×100
[0079] A x : Initial absorbance of pathogenic bacteria suspension; A y : Initial absorbance of probiotic suspension; A t(x+y) : The absorbance value of the supernatant of the mixed bacterial suspension after static culture for th.
[0080] The results are shown in Table 5.
[0081] Table 5
[0082]
[0083] From the data results in Table 5, it can be seen that LC24 and LRa05 had obvious copolymerization with Helicobacter pylori within 2 h, and the copolymerization rate reached more than 30%. Moreover, with the extension of time, the copolymerization ability of LC24 and LRa05 with Helicobacter pylori gradually increased, reaching a higher copolymerization rate at 24 h, which was 62.27% and 57.72%, respectively. LC24 and LRa05 have a high copolymerization ability against Helicobacter pylori.
[0084] Laser confocal microscopy was used to further confirm the existence of coaggregation. The operation was as follows: the third generation of Helicobacter pylori SS1 was centrifuged, washed twice with artificial gastric juice, and resuspended in artificial gastric juice. The OD of the Helicobacter pylori SS1 suspension was adjusted. 600 The concentration of the prestained Helicobacter pylori SS1 and LC24 bacterial suspension or LRa05 bacterial suspension was 0.50, and the suspension was stained with the fluorescent dye CFDA SE and incubated at 37°C for 30 minutes. The bacteria were then resuspended in PBS to remove excess dye. The prestained Helicobacter pylori SS1 and LC24 bacterial suspension or LRa05 bacterial suspension were mixed in equal volumes, mixed on a vortex oscillator for 10 seconds, and incubated at 37°C for 2 hours. The mixed bacterial solution was collected, 1 drop was dropped on a glass slide, and observed with a laser confocal microscope under the operating conditions of Ex=494 nm and Em=521 nm.
[0085] The results are as follows Figure 1 As shown, a, b, and c are the bright field, dark field, and superimposed field views of Helicobacter pylori SS1 cultured alone under a laser confocal microscope, respectively. It can be observed that the SS1 strain is evenly dispersed and no co-aggregates are formed; d, e, and f are the bright field, dark field, and superimposed field views of LC24 and SS1 after co-culture for 2 h, respectively; g, h, and i are the bright field, dark field, and superimposed field views of LRa05 and SS1 after co-culture for 2 h, respectively; it was observed that LC24 or LRa05 and SS1 (green fluorescence) aggregated with each other to form multiple large-area aggregates (white arrows), indicating that LC24 or LRa05 can better aggregate with Helicobacter pylori and encapsulate it and excrete it from the body, which is beneficial to reduce the colonization of Helicobacter pylori in the stomach.
[0086] Example 6
[0087] The improvement effect of the strain on the mouse model of Helicobacter pylori infection:
[0088] (1) Experimental animals: Healthy female SPF-grade C57BL / 6 mice, 8 weeks old (54 mice), were housed in a controlled environment with room temperature maintained at 22-24°C, humidity at 50-60%, and a 12-h light / dark cycle. They were allowed to eat and drink freely.
[0089] (2) Animal grouping: After one week of adaptive feeding, the mice were randomly divided into 9 groups, with 6 mice in each group: blank group (CG), model group (MG), quadruple drug treatment group (PG), LC24 group (intervention with LC24 bacterial solution), LRa05 group (intervention with LRa05 bacterial solution), LC24+LRa05 group 1 (combined intervention with LC24 bacterial solution and LRa05 bacterial solution, with a live bacteria count ratio of 1:1), LC24+LRa05 group 2 (combined intervention with LC24 bacterial solution and LRa05 bacterial solution, with a live bacteria count ratio of 5:1), LC24+LRa05 group 3 (combined intervention with LC24 bacterial solution and LRa05 bacterial solution, with a live bacteria count ratio of 1:5), and ATCC25302+LRa05 group (combined intervention with commercially available Lactobacillus paracasei ATCC25302 bacterial solution and LRa05 bacterial solution, with a live bacteria count ratio of 1:1).
[0090] (3) Animal modeling and intervention methods:
[0091] The Helicobacter pylori SS1 strain frozen at -80℃ was revived on Columbia agar plates containing 5% sterile defibrinated sheep blood. After two generations of activation, the strain was cultured in Columbia blood plates for 48 hours and then washed with BHI liquid medium to obtain SS1 bacterial solution, and its concentration was adjusted to 1×10 10CFU / mL, and then used for inoculation of animal experiments. After one week of adaptive feeding, mice were fasted for 12 hours and deprived of water for 4 hours. They were first gavaged with 0.25 mL of 0.2 mol / L sodium bicarbonate solution, and then gavaged with 0.3 mL of SS1 bacterial solution (1×10 10 CFU / mL), gavage once every other day, and the above operation was performed 5 times in total.
[0092] The experiment lasted for 6 weeks.
[0093] Blank group (CG): 0.2 mL 0.9% NaCl was administered intragastrically daily from week 1 to week 6.
[0094] Model group (MG): 0.2 mL of 0.9% NaCl was gavaged daily from week 1 to week 6, and infection and modeling were started in the above manner in week 2.
[0095] Quadruple drug treatment group (PG): normal feeding in the first week; infection modeling started as above in the second week, and 0.2 mL of amoxicillin (410 mg / kg), bismuth pectin (123 mg / kg), furazolidone (41 mg / kg), and pantoprazole (16.4 mg / kg) were gavaged daily in weeks 2-3; 0.2 mL of 0.9% NaCl was gavaged daily in weeks 4-6.
[0096] Each probiotic intervention group: Daily intragastric administration of 0.2 mL of probiotics or compound probiotics (1×10 8 CFU / g ▪bw), and infection modeling was started in the second week as described above.
[0097] (4) Blood and tissue sample processing:
[0098] After the last intragastric administration, the mice were fasted for 12 h, anesthetized by intraperitoneal injection of 4% chloral hydrate solution, blood was collected from the eyeballs, centrifuged at 3500 r / min for 20 min at 4°C, and serum was collected in EP tubes and frozen at -80°C for later use. The mice were killed, and the stomach and other tissues of the mice were collected and stored in a -80°C refrigerator.
[0099] (5) Indicator analysis:
[0100] (5.1) Helicobacter pylori colonization of gastric tissue:
[0101] Gastric tissues of mice in the model group were obtained, homogenized and cultured on Brucella agar plates for 3 days, and the colonies were subjected to Gram staining. Figure 2 As shown, under the microscope, Helicobacter pylori cells can be clearly shown to be in the typical morphology of red S-shape, micro-spiral or curved rod-shape, which is a Gram-negative bacterium. This confirms that the Helicobacter pylori infection has been successfully modeled and Helicobacter pylori colonization in the gastric mucosal tissue has occurred.
[0102] (5.2) Effect of probiotic intervention on serum anti-Hp-IgG antibody levels in infected mice:
[0103] ELISA was used to detect anti-Hp-IgG antibodies. 100 µL of serum samples from each group diluted 1:50 were added to the microwells coated with Helicobacter pylori (Hp) antigen, reacted at 37°C for 30 min, and washed 3 times. 100 µL of rabbit anti-mouse IgG antibody labeled with horseradish peroxidase (HRP) was added to each well, reacted at 37°C for 30 min, and washed 3 times. 100 µL of TMB substrate (tetramethylbenzidine) was added to each well, reacted at 25°C in the dark for 15 min, and 50 µL of H2SO4 stop solution was added. The absorbance of each well was measured by an enzyme reader at λ=450nm, and the standard curve was drawn with the concentration of the standard as the horizontal axis and the OD value as the vertical axis. The content of anti-Hp-IgG antibodies in mouse serum was calculated by the standard curve.
[0104] The results are as follows Figure 3 As shown, compared with the model group, the level of anti-Hp-IgG antibodies in the mouse serum was significantly reduced after intervention with probiotics in each group, which was close to the level of anti-Hp-IgG antibodies in the uninfected blank group of mice, indicating that the probiotics involved in the present invention can be comparable to the level of the quadruple antibiotic treatment group of the standard first-line treatment regimen for Helicobacter pylori infection, and the combination intervention of LC24 and LRa05 has a better effect in reducing the level of anti-Hp-IgG antibodies.
[0105] (5.3) Effects of probiotic intervention on serum endotoxin and inflammatory factor levels in infected mice:
[0106] The detection was performed with reference to the kits for endotoxin (ET), interleukin-17A (IL-17A), interleukin-23 (IL-23), interferon-β (IFN-β), interferon-γ (IFN-γ), and forkhead box protein P3 (Foxp3). The specific operation was performed according to the instructions of the kits.
[0107] Depend on Figure 4 The results showed that the probiotic intervention group could reduce the endotoxin level in serum. Compared with the model group, the endotoxin level in each probiotic group was reduced to varying degrees, and the effect was comparable to that of the quadruple drug treatment group of the standard first-line treatment for Helicobacter pylori infection. The probiotic group with a combination of LC24 and LRa05 had a better reduction effect, indicating that the probiotics involved in the present invention can reduce the endotoxin produced by Helicobacter pylori infection and its harm to the body.
[0108] Depend on Figure 5 and Figure 6 The results showed that compared with the model group, the IL-17A and IL-23 levels in the serum of mice in each probiotic intervention group were significantly reduced, and the LC24 and LRa05 combined probiotic group had a better reduction effect.
[0109] Depend on Figure 7 and Figure 8 The results showed that compared with the model group, the IFN-β and IFN-γ levels in the serum of mice in each probiotic intervention group were significantly increased, and the LC24 and LRa05 combined probiotic group had a better effect.
[0110] Depend on Fig. 9 The results showed that compared with the blank group, the expression level of Foxp3 protein in the model group was significantly decreased; compared with the model group, each probiotic intervention group could significantly increase the expression level of FoxP3 protein, especially the LC24 and LRa05 compound probiotic group.
[0111] The above results indicate that the probiotics of the present invention can reduce the endotoxin produced by Helicobacter pylori infection, and can inhibit the inflammatory response caused by Helicobacter pylori infection by regulating the transcription factor FoxP3 of the inflammatory response of mice.
[0112] (5.4) Effects of probiotic intervention on oxidative stress in infected mice:
[0113] Mouse serum samples were tested with reference to the catalase (CAT) and superoxide dismutase (SOD) detection kits. Specific operations were performed according to the instructions of the kits.
[0114] Depend on Fig.10 and Fig.11 The results showed that compared with the model group, the CAT and SOD in the serum of mice in the quadruple antibiotic treatment group and the different probiotic intervention groups were significantly increased, especially the probiotic intervention with the combination of LC24 and LRa05 had a better effect, indicating that the probiotic intervention involved in the present invention can enhance the host's antioxidant stress response and relieve inflammation.
[0115] (5.6) Effects of probiotic intervention on gastric pepsin in infected mice:
[0116] The gastric tissues of mice in each group were taken, and the pepsin activity in the gastric tissues of mice was detected by referring to the pepsin activity kit.
[0117] Depend on Fig.12 The results showed that compared with the model group, the pepsin in the gastric tissue of mice in the quadruple antibiotic treatment group and the LC24 and LRa05 combined probiotic intervention group was significantly increased, while there was no significant difference between the LC24 group and the LRa05 group, indicating that the composite probiotic intervention involved in the present invention can increase the pepsin activity in the host's gastric tissue and alleviate the damage caused by Helicobacter pylori infection.
[0118] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
[0119] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
[0120] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. A probiotic for resisting Helicobacter pylori infection, characterized in that: The strain in the probiotic for resisting Helicobacter pylori infection is Lactobacillus paracasei with a preservation number of CGMCC No.24411. Lactobacillus paracasei LC24 strain and Lactobacillus rhamnosus with a deposit number of CGMCC No. 24377 Lactobacillus rhamnosus LRa05 strain composition; the ratio of the number of viable bacteria of the LC24 strain to the LRa05 strain is 1:5-5:1; The live bacteria content of the strain in the probiotic is not less than 1×10 9 CFU / g or 1×10 9 CFU / mL.
2. The probiotic according to claim 1, characterized in that The dosage form of the probiotics includes solution, lyophilized powder, capsule, tablet or granule.
3. The probiotic according to claim 2, characterized in that The dosage form of the probiotic is a solution, which is prepared by the following method: The LC24 strain and the LRa05 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively and resuspended with a solvent to obtain a LC24 bacterial suspension and a LRa05 bacterial suspension; the LC24 bacterial suspension and the LRa05 bacterial suspension are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent.
4. The probiotic according to claim 2, characterized in that The dosage form of the probiotic is a freeze-dried powder, which is prepared by the following method: The LC24 strain and the LRa05 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively, mixed with a protective agent and freeze-dried to obtain LC24 bacterial powder and LRa05 bacterial powder; the LC24 bacterial powder and the LRa05 bacterial powder are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent.
5. Use of the probiotic according to any one of claims 1 to 4 in the preparation of a drug for resisting Helicobacter pylori infection.
6. The use according to claim 5, characterized in that: The medicine also contains auxiliary materials.
7. The use according to claim 6, characterized in that: The auxiliary materials include any one of fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, colorants, pH regulators, antioxidants, antibacterial agents or buffers, or a combination of at least two of them.
Citation Information
Patent Citations
Composition for resisting helicobacter pylori and application of composition
CN109480231A
Lactobacillus rhamnosus LRa05 for antagonizing shigella, screening method and application of lactobacillus rhamnosus LRa05
CN112210507A
Lactobacillus paracasei for preventing and treating helicobacter pylori infection as well as composition and application of lactobacillus paracasei
CN114958650A
Lactobacillus paracasei for improving chronic low-grade inflammation and application of lactobacillus paracasei
CN116478874A
Probiotic agent for improving mental diseases caused by environmental pollution by adjusting intestine-brain axis and application thereof
CN116509902A
